Terns Pharmaceuticals (NASDAQ:TERN) Given “Neutral” Rating at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Terns Pharmaceuticals (NASDAQ:TERN) in a research note published on Wednesday morning, Marketbeat.com reports. HC Wainwright currently has a $53.00 price objective on the stock.

Other analysts have also issued research reports about the company. Oppenheimer upped their price objective on Terns Pharmaceuticals from $28.00 to $58.00 and gave the company an “outperform” rating in a report on Tuesday, December 9th. Wall Street Zen cut shares of Terns Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Terns Pharmaceuticals in a report on Monday, December 29th. Leerink Partners started coverage on Terns Pharmaceuticals in a research report on Monday, February 9th. They set an “outperform” rating and a $58.00 price objective for the company. Finally, Barclays raised their price objective on Terns Pharmaceuticals from $36.00 to $56.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 9th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $57.33.

Terns Pharmaceuticals Stock Performance

Shares of NASDAQ TERN opened at $52.86 on Wednesday. The stock has a fifty day moving average price of $40.63 and a two-hundred day moving average price of $28.57. The firm has a market cap of $5.48 billion, a P/E ratio of -51.32 and a beta of -0.31. Terns Pharmaceuticals has a 1 year low of $1.87 and a 1 year high of $52.98.

Insider Activity at Terns Pharmaceuticals

In related news, insider Emil Kuriakose sold 1,155 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $38.57, for a total value of $44,548.35. Following the completion of the sale, the insider owned 50,365 shares in the company, valued at approximately $1,942,578.05. This represents a 2.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Amy L. Burroughs sold 14,583 shares of Terns Pharmaceuticals stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $46.71, for a total transaction of $681,171.93. Following the transaction, the chief executive officer owned 288,976 shares in the company, valued at approximately $13,498,068.96. The trade was a 4.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 170,409 shares of company stock valued at $6,563,769. 1.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Terns Pharmaceuticals during the fourth quarter valued at $25,000. GAMMA Investing LLC increased its stake in Terns Pharmaceuticals by 762.4% in the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock valued at $35,000 after buying an additional 770 shares during the period. Engineers Gate Manager LP purchased a new stake in Terns Pharmaceuticals in the 2nd quarter worth approximately $41,000. iA Global Asset Management Inc. acquired a new stake in shares of Terns Pharmaceuticals during the 4th quarter valued at $43,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Terns Pharmaceuticals during the 2nd quarter valued at $46,000. Hedge funds and other institutional investors own 98.26% of the company’s stock.

More Terns Pharmaceuticals News

Here are the key news stories impacting Terns Pharmaceuticals this week:

• Positive Sentiment: Merck agreed to an all-cash acquisition at $53.00 per share, approved by both boards and structured as a tender offer with expected closing in Q2 2026 — the deal provides a clear near-term valuation floor and validates Terns’ lead asset, TERN-701, as strategically valuable to a large pharma buyer. Read More.
• Positive Sentiment: Major media and wire services emphasize the strategic fit (adding a CML allosteric BCR::ABL1 inhibitor) and Merck’s broader push to refill its oncology pipeline ahead of Keytruda’s patent cliff — reinforcing deal rationale for investors. Read More.
• Neutral Sentiment: HC Wainwright reaffirmed a “neutral” rating with a $53 price target (essentially aligned with the offer price), suggesting limited upside beyond the transaction price while the deal closes. Read More.
• Neutral Sentiment: Deal mechanics: transaction is a tender offer contingent on shareholder participation and customary closing conditions — market will watch vote/acceptance levels, regulatory review and timing rather than Terns’ standalone clinical milestones. Read More.
• Negative Sentiment: Multiple shareholder-law firms have launched investigations into whether Terns’ board obtained a fair price (Monteverde, Ademi, Halper Sadeh), which could lead to litigation, delay or pressure on deal terms — a risk for timing and transaction certainty. Read More. Read More. Read More.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.